Company Overview

Exploration and development of their 100% owned Tampu, Wiltshire and Kalannie kaolin projects along with the 100% owned Bonnie Rock silica project which are all located in the mid-west of Western Australia.

Directors and Management

Mr Derek Hall

Company Secretary 30/12/2019

Mr Hall is a finance and compliance specialist in the listed space. Mr Hall has commercial experience identifying key business drivers and bringing cost control and process improvement into sharp focus. Mr Hall has been involved as a Chief Financial Officer and Company Secretary for a number of publicly listed and unlisted companies involving transactions in technology, mining, oil and gas and construction.

FFinSIA,MICS&A, AGIA Chartered Accountant Male

Mr Harry Karelis

Non-Executive Director --

--

BSc(Hons) Biochem & Micro, MBA, FFSIA, CFA, FAICD Male

Mr Leslie Harold Webb

Non-Executive Director --

Mr Webb was establishing ITV Consulting Pty Limited, a corporate advisory and investment consulting business. He is also a Non-executive Director of pharmaceutical company Generic Health Limited and health insurance company iSelect. He previously sat on the Board of the ASX listed Gradipore Ltd (now Life Therapeutics).

AICD Solicitor, Barrister Male

Mr David Dodd

Chairman --

Mr Dodd's experience includes management and corporate development experience in the life sciences industry. Prior to joining the Stem Cell Sciences, he was President, Chief Executive Officer and Director of NASDAQ quoted Serologicals Corporation until it was acquired by Millipore Corporation on 14 July 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board for the Pharmaceutical Sector for Solvay SA. He was also Chairman of the Board of Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. He was awarded the 2005 GBP Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. In addition, he received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the USA and the United Kingdom. David is also currently serving on the board of directors of Stheno Corporation, a private life sciences instrument company, as Non-executive Director; as Chairman of the Board of the American Foundation for Suicide Prevention; and, as Immediate Past-Chair, the Georgia Biomedical Partnership, and the biotechnology trade association in the State of Georgia. He was appointed President, CEO and Chairman of Bioreliance Corporation on 3 December 2007.

B.Sc, M.Sc, Adv Mgt Program (Harvard) Male

Dr Peter Mountford

Non-Executive Director --

Dr Mountford is currently a Director of all the companies within Stem Cell Sciences, as well as of the private company Secure Sciences Pty Ltd.

PhD (Biology), Post Doctoral Research Male

Dr Michael (Mike) Dexter

Non-Executive Director --

Dr Dexter spent the five years prior to joining Stem Cell Sciences as Director (Chief Executive Officer) of The Wellcome Trust. During his time at The Wellcome Trust, he oversaw one of the biggest advances in biomedical research when it was announced that the human genome had been sequenced - giving scientists a detailed map of the body's make-up for the first time. Prior to joining The Wellcome Trust, he was Director of Research at the Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester. He is a Fellow of the Royal Society (London), was appointed Professor of Experimental Oncology at the University of Manchester and is an honorary Fellow of the Royal College of Physicians and a founding fellow of the Academy of Medical Sciences. He is currently Chairman of the International Centre for Life, Newcastle, and the Cockcroft Institute for Accelerator Sciences in Daresbury, Cheshire. He was previously a Director of Catalyst Biomedica Ltd, the translational business arm of The Wellcome Trust. He has over 360 publications on his scientific work.

PhD Male

Dr Alastair James Riddell

Chief Executive Officer --

Dr Riddell has more than 24 years experience in this industry. He has spent time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007, he held the position of Non-executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, he was Chief Executive Officer of Pharmagene for seven years, during which time he listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. He began his professional career as a medical doctor with six years, experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007, he joined the Board of Sareum Holdings plc as Non-executive Director.

Doctor Male

Mr Anthony (Tony) Stephen Cormack

Non-Executive Director 23/04/2021

--

BSc(AppGeology),MAusIMM Geologist Male

Mr Philip Re

Non-Executive Director 23/04/2021

--

CA, CS, MAICD Male

Mr Peter Woods

Non-Executive Director 23/04/2021

--

GDAFIN, BCom Male

Mr Daniel Coletta

Joint Company Secretary 11/12/2020

Mr Coletta has experience in accounting and compliance.

Male

Top 20 Shareholders

Director Transactions